公开(公告)号：US20060178371A1

公开(公告)日：2006-08-10

申请号：US11395676

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Carmen Alvarez ,  Tin-Yau Chan ,  Chad Knutson ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Carmen Alvarez ,  Tin-Yau Chan ,  Chad Knutson ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

IPC分类号： A61K31/519 ,  A61K31/7048 ,  A61K31/704 ,  A61K31/525 ,  A61K31/66 ,  C07D487/04

CPC分类号： C07D487/04

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

公开(公告)号：US20070054925A1

公开(公告)日：2007-03-08

申请号：US11396079

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04 ,  A61K31/495

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

公开(公告)号：US20070054906A1

公开(公告)日：2007-03-08

申请号：US11396001

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

IPC分类号： A61K31/5377 ,  A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

摘要翻译： 在其许多实施方案中，本发明提供了一类新颖的吡唑并[1,5-a]嘧啶化合物作为细胞周期蛋白依赖性激酶的抑制剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备药物制剂的方法 包括一种或多种这样的化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。

公开(公告)号：US20070275983A1

公开(公告)日：2007-11-29

申请号：US11779050

申请日：2007-07-17

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhenmin He ,  Ray James ,  Haengsoon Park

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhenmin He ,  Ray James ,  Haengsoon Park

IPC分类号： A61K31/519 ,  A61K38/14 ,  A61K31/704 ,  A61K31/7072 ,  A61K31/52

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/52 ,  A61K31/704 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

摘要翻译： 在其许多实施方案中，本发明提供了一类新颖的吡唑并[1,5-a]嘧啶化合物作为细胞周期蛋白依赖性激酶的抑制剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备药物制剂的方法 包括一种或多种这样的化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。

公开(公告)号：US20070076738A1

公开(公告)日：2007-04-05

申请号：US11242152

申请日：2005-10-03

申请人： James Ludwig ,  Matthew Perry ,  Lawrence Dillard

发明人： James Ludwig ,  Matthew Perry ,  Lawrence Dillard

IPC分类号： H04L12/28

CPC分类号： H04L41/12 ,  H04L41/08 ,  H04L43/00 ,  H04L43/045

摘要： A system, method, and computer-readable medium for resource migration in a distributed telecommunication system is provided. Respective sets of performance parameters of a first plurality of nodes disposed in a first node group and a second plurality of nodes in a second node group are collected. Service capabilities of the first node group and the second node group are evaluated based on the sets of performance parameters. One node group of the first node group and the second node group is designated as a currently preferred node group in response to evaluation of the service capabilities. The steps of collecting, evaluating, and designating are repeated a plurality of times. The currently preferred node group is designated as an active preferred node group in the event that a sequence of evaluating service capabilities each results in the one node group being designated as the currently preferred node group.

摘要翻译： 提供了一种用于分布式电信系统中的资源迁移的系统，方法和计算机可读介质。 收集设置在第一节点组中的第一多个节点和第二节点组中的第二多个节点的各组性能参数。 基于性能参数的集合来评估第一节点组和第二节点组的服务能力。 响应于服务能力的评估，第一节点组和第二节点组的一个节点组被指定为当前优选的节点组。 收集，评估和指定的步骤重复多次。 在评估服务能力的序列各自导致一个节点组被指定为当前优选节点组的情况下，将当前优选的节点组指定为活动的优选节点组。

公开(公告)号：US20060173016A1

公开(公告)日：2006-08-03

申请号：US11395824

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

IPC分类号： A61K31/517 ,  C07D487/04

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/52 ,  A61K31/704 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

公开(公告)号：US20050222203A1

公开(公告)日：2005-10-06

申请号：US10775963

申请日：2004-02-10

申请人： Jeffrey Letourneau ,  Vidyahar Paradkar ,  Michael Ohlmeyer ,  Lawrence Dillard ,  John Baldwin ,  Christopher Riviello ,  Angela Wong ,  Yaing Rong

发明人： Jeffrey Letourneau ,  Vidyahar Paradkar ,  Michael Ohlmeyer ,  Lawrence Dillard ,  John Baldwin ,  Christopher Riviello ,  Angela Wong ,  Yaing Rong

IPC分类号： A61K31/4184 ,  A61K31/4188 ,  A61K31/428 ,  A61K31/47 ,  C07D215/38 ,  C07D235/30 ,  C07D277/62 ,  C07D277/82 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

CPC分类号： C07D215/38 ,  C07D235/30 ,  C07D277/82 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

摘要： Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed. A representative example is

摘要翻译： 具有羧酸酯末端的氮杂环联芳烃可用于治疗子宫内膜异位症，骨质疏松症，血管成形术后的再狭窄，类风湿性关节炎，癌症，黄斑变性和肥胖症。 公开了式的化合物。 一个代表性的例子是

公开(公告)号：US20070037824A1

公开(公告)日：2007-02-15

申请号：US10654546

申请日：2003-09-03

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Alan Mallams ,  Carmen Alvarez ,  Kartik Keertikar ,  Jocelyn Rivera ,  Tin-Yau Chan ,  Vincent Madison ,  Thierry Fischmann ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park ,  Vidyadhar Paradkar ,  Douglas Hobbs

IPC分类号： A61K31/519 ,  C07D487/02

CPC分类号： C07D487/04

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

公开(公告)号：US20060235025A1

公开(公告)日：2006-10-19

申请号：US11395974

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Lawrence Dillard ,  Vinh Tran ,  Zhen He ,  Ray James ,  Haengsoon Park

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

公开(公告)号：US20060173017A1

公开(公告)日：2006-08-03

申请号：US11395965

申请日：2006-03-31

申请人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Chad Knutson ,  Brian McKittrick ,  Lawrence Dillard ,  Vinh Tran ,  Zhen Min He ,  Ray James ,  Haengsoon Park

发明人： Timothy Guzi ,  Kamil Paruch ,  Michael Dwyer ,  Ronald Doll ,  Viyyoor Girijavallabhan ,  Chad Knutson ,  Brian McKittrick ,  Lawrence Dillard ,  Vinh Tran ,  Zhen Min He ,  Ray James ,  Haengsoon Park

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04

摘要： In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

摘要翻译： 在其许多实施方案中，本发明提供了一类新颖的吡唑并[1,5-a]嘧啶化合物作为细胞周期蛋白依赖性激酶的抑制剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备药物制剂的方法 包括一种或多种这样的化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。